SYSTEM AND METHOD FOR AUTOMATED DOSAGE CALCULATION AND PATIENT TREATMENT LIFE CYCLE

• US 20160267252A1
• Filed: 05/25/2016
• Published: 09/15/2016
• Est. Priority Date: 07/13/2011
• Status: Active Grant

• Current Assignee: The Sottopelle Group LLC
• Original Assignee: SottoPelle, Inc.
• Inventors: Tutera, Gino
• Granted Patent: US 10,325,075 B2
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: G06Q 10/00 Administration; Management
• CPC Class Codes: G16H 10/20 for electronic clinical trials or questionnaires
• CPC Class Codes: G16H 10/60 for patient-specific data, e.g. for electronic patient records
• CPC Class Codes: G16H 20/10 relating to drugs or medications, e.g. for ensuring correct administration to patients
• CPC Class Codes: G16H 40/20 for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
• CPC Class Codes: G16H 40/67 for remote operation
• CPC Class Codes: G16H 50/20 for computer-aided diagnosis, e.g. based on medical expert systems
• CPC Class Codes: G16H 50/70 for mining of medical data, e.g. analysing previous cases of other patients

Abstract

A system and method for automatically calculating an accurate recommended dosage for hormone replacement therapy and automating the life cycle of a patient'"'"'s treatment over time. The system and method can automatically acquire relevant patient parameters and apply a consistent formulaic approach to help reduce incorrect dosage determinations. A pellet insertion size may be determined and documented based on a calculated dosage, and an insertion side and lot numbers may be tracked and managed. In addition, corresponding revenues may be tracked and profitability may be reported for hormone replacement therapy practices.

Claims

1. A system for determining a dosage of a hormone to be administered to a patient, the system comprising:

an input device;

a display screen; and

at least one electronic circuit configured to perform the following operations;

receiving, from the input device, an input signal of a user indicating an input directed to a patient sex and a patient status, wherein the patient status is automatically determined by the electronic circuit and includes at least one of a new patient, a returning patient and a booster patient;

if the patient sex is female, determining by the electronic circuit an effective estradiol dosage and an effective testosterone dosage using dosage calculation methods selected based on the patient status, automated female input parameters, and female tracking parameters;

if the patient sex is male, determining by the electronic circuit an effective testosterone dosage using dosage calculation methods selected based on the patient status, automated male input parameters, and male tracking parameters; and

displaying, on the display screen, the determined effective dosages.

2. The system according to claim 1, wherein the automated female input parameters and the automated male input parameters include at least one of a physical activity level, a quantity of patient visits, patient age, patient height, weight, race, number of pregnancies, number of live births, number of abortions, history of renal disease, active liver disease, hysterectomy, history of cervical cancer, history of ovarian cancer, history of fibrocystic breast disease, history of breast cancer, current follical stimulating hormone (FSH) level, current testosterone level, current estradiol level, current non-pellet estradiol dose, current non-pellet testosterone dose, history of acne, history of facial hair, history of hair loss, history of prostate cancer, history of polycystic ovary syndrome (PC OS), history of hysterectomy, history of heavy menses, and history of metabolic syndrome.

3. The system according to claim 1, wherein the dosage calculation methods include tracking at least one of a pellet insertion location, a pellet insertion side, a pellet dose, pellet lot numbers, insertion notes, a previous testosterone dose, and a previous estradiol dose.

4. The system according to claim 1, wherein the dosage calculation methods are configured to apply a pellet allocation algorithm to determine an estradiol pellet size insertion corresponding to the effective estradiol dosage and a testosterone pellet size insertion corresponding to the effective testosterone dosage, wherein a quantity of the estradiol pellet size insertion and the testosterone pellet size insertion are minimized.

5. A computer-implemented method of providing a dosage and a patient treatment life-cycle on a device comprising an electronic circuit, an input device, and a display screen, the method comprising:

receiving, using the device, an input signal of a user indicating an input directed to a patient sex and a patient status, wherein the patient status is automatically determined by the electronic circuit and includes at least one of a new patient, a returning patient and a booster patient;

if the patient sex is female, determining by the electronic circuit an effective estradiol dosage and an effective testosterone dosage using dosage calculation methods selected based on the patient status, automated female input parameters, and female tracking parameters;

if the patient sex is male, determining by the electronic circuit an effective testosterone dosage using dosage calculation methods selected based on the patient status, automated male input parameters, and male tracking parameters; and

displaying, on the display screen, the determined effective dosages.

9. The method according to claim 9, wherein using dosage calculation methods selected based on the female tracking parameters and the male tracking parameters includes tracking at least one of a pellet insertion location, a pellet insertion side, a pellet dose, pellet lot numbers, insertion notes, a previous testosterone dose, and a previous estradiol dose.

6. The method according to claim 9, wherein the automated female input parameters and the automated male input parameters include at least one of a physical activity level, a quantity of patient visits, patient age, patient height, weight, race, number of pregnancies, number of live births, number of abortions, history of renal disease, active liver disease, hysterectomy, history of cervical cancer, history of ovarian cancer, history of fibrocystic breast disease, history of breast cancer, current follical stimulating hormone (FSH) level, current testosterone level, current estradiol level, current non-pellet estradiol dose, current non-pellet testosterone dose, history of acne, history of facial hair, history of hair loss, history of prostate cancer, history of polycystic ovary syndrome (PCOS), history of hysterectomy, history of heavy menses, and history of metabolic syndrome.

8. The method according to claim 9, wherein determining the effective dosages is base on input parameters including at least one of a physical activity level, a quantity of patient visits, patient age, patient height, weight, race, number of pregnancies, number of live births, number of abortions, history of renal disease, active liver disease, hysterectomy, history of cervical cancer, history of ovarian cancer, history of fibrocystic breast disease, history of breast cancer, current follical stimulating hormone (FSH) level, current testosterone level, current estradiol level, current non-pellet estradiol dose, current non-pellet testosterone dose, history of acne, history of facial hair, history of hair loss, history of prostate cancer, history of polycystic ovary syndrome (PCOS), history of hysterectomy, history of heavy menses, and history of metabolic syndrome.

11. The method according to claim 9, wherein using dosage calculation methods includes applying a pellet allocation algorithm to determine an estradiol pellet size insertion corresponding to the effective estradiol dosage and a testosterone pellet size insertion corresponding to the effective testosterone dosage, wherein a quantity of the estradiol pellet size insertion and the testosterone pellet size insertion are minimized.

13. The method according to claim 9, further comprising the steps of:

displaying an estradiol pellet size insertion corresponding to the effective estradiol dosage and a testosterone pellet size insertion corresponding to the effective testosterone dosage;

receiving a user indication of at least one of an increase and a decrease in at least one of the estradiol pellet size insertion and the testosterone pellet size insertion; and

calculating an updated effective estradiol dosage and an updated effective testosterone dosage based on the user indication.

10. The method according to claim 15, wherein tracking the pellet insertion location and the pellet insertion side is based on historical insertion information including at least one of a hip location, an abdominal location, a left side, and a right side.

7. The method according to claim 10, wherein the dosage method for a female booster and return patient further includes:

receiving, by the electronic circuit, female non-pellet tesetosterone usage, whether patient is pre-menopausal, estradiol level, and whether patient has migraines;

if patient is pre-menopausal with estradiol level greater than 10 milligrams and patient has mirgaines, determining, by the electronic circuit, an estradiol dosage=0; and

if patient uses non-pellet testosterone, determining, by the electronic circuit, a testosterone dosage=0.

12. The method according to claim 20, wherein the pellet allocation algorithm includes:

providing a plurality of pellet sizes ordered from largest to smallest;

subtracting a largest of the plurality of pellet sizes from the effective dosage;

if a result of the subtraction is greater than zero, assigning the largest of the plurality of pellet sizes as the estradiol pellet size insertion or the testosterone pellet size insertion;

if a result of the subtraction is less than zero, subtracting a next smallest one of the plurality of pellet sizes from the effective dosage until the result is greater than zero;

taking an absolute value of the result of the subtraction that is less than zero and of the result of the subtraction that is greater than zero; and

assigning one of the plurality of pellet sizes as the estradiol pellet size insertion or the testosterone pellet size insertion corresponding to the result having a lesser absolute value.